Clin2
NCT06834100Possibly a fitRecruiting

Comparing a new meningitis vaccine to an approved one

InfectionsMeningococcal

Part of Infections clinical trials.

This trial tests a new meningitis vaccine (GNG-DE) to see how well it works compared to a vaccine already on the market. It might help protect you or your child from meningococcal disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
240 people
Ages
3 years to 55 years
Study type
Interventional

Who can take part

  • You are between 3 and 55 years old.
  • You do not currently have a COVID-19 infection (confirmed by a rapid test).
  • You have not had a meningitis vaccine, certain other vaccines, or certain medications recently (see full list).
  • You are willing to use reliable birth control if you are of childbearing age (14–55).
  • You have no serious chronic illnesses, history of seizures, or previous bad reactions to vaccines.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07374510Not yet recruiting· Phase 1
Meningococcal vaccine trial for ages 2 to 59

This trial tests a new vaccine that helps protect against 6 types of meningococcal bacteria, which can cause serious infections like meningitis. It is for healthy people aged 2 to 59 years.

NCT07505810Recruiting· Phase 3
Meningitis vaccine trial for infants 3-5 months old

This trial tests a vaccine that protects against four types of meningococcal bacteria (groups A, C, W, and Y) in healthy babies aged 3 to 5 months. The vaccine is given to help prevent meningitis and other serious infections.

Nanning, Guangxi
NCT07505823Recruiting· Phase 3
Meningococcal vaccine trial for infants 6-11 months old

This study tests whether a new vaccine safely protects infants aged 6 to 11 months against four types of meningococcal bacteria that can cause serious infections like meningitis and blood infections. It is designed for healthy babies who have not yet received any meningococcal vaccine.

Nanning, Guangxi
NCT07505836Recruiting· Phase 3
Meningitis vaccine trial for toddlers aged 12–23 months

This study tests a vaccine that protects against four common types of meningitis (groups A, C, Y, and W135) in toddlers aged 12–23 months. It helps researchers see if the vaccine is safe and works well for young children.

Nanning, Guangxi
NCT07204457Recruiting· Phase 2/Phase 3
Meningococcal vaccine trial for healthy adults 19 to 55 years old

This trial tests a new meningococcal conjugate vaccine (EG-MCV4) in healthy adults to see how well the body's immune system responds and if it's safe. If you qualify, you'd help researchers learn if this vaccine can prevent meningococcal disease.

Seoul
NCT07395739Recruiting· Phase 1
Safety and immune response test of a new meningitis B vaccine

This trial tests a new vaccine called DX-104 to see if it is safe and helps the body fight meningitis B. Healthy adults aged 18-50 can join to help find a better way to prevent this infection.

Perth, Western Australia

Hear when a new Infections trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.